Select for export Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms Details DOI 10.3929/ethz-c-000793359 Copy citation Copy BibTeX Repository for Publications and Research Data (ETH Zurich) 2026-01-19 Martina Colognesi, Daniela Gabbia, Anna Signor, Miles Sarill, Lucia Centofanti, Andrea Rinaldi OpenAlex Published psilocybin PharmacologyMechanism of ActionReceptor Pharmacology Other Endocrinology More